Back to results
US 12,758,582 B2Granted
Anti-CD33 antibodies and uses thereof
AssigneeFred Hutchinson Cancer Center
InventorsRoland B. Walter, George S. Laszlo
Life of this patent
Estimating the term…
Abstract
A suite of novel anti-CD33 antibodies is described. The provided antibodies are pan-binders, binding the C2-set Ig-like domain in the presence or absence of the V-set Ig-like domain of CD33; are C2-set specific binders, binding the C2-set Ig-like domain only in the absence of the V-set Ig-like domain of CD33; or are V-set binders, binding the V-set Ig-like domain of CD33. The antibodies provide novel therapeutic and diagnostic tools against CD33-related disorders, such as acute myeloid leukemia (AML).
Claims18
A CD33-binding antibody or antigen biding fragment thereof comprising a binding domain comprising a six-member complementarity determining region (CDR) set having a CDR light chain (L) 1, a CDRL2, a CDRL3, a CDR heavy chain (H) 1, a CDRH2, a CDRH3, wherein:
- (i) the CDRL1 has the sequence of SEQ ID NO:
- 20,
- the CDRL2 has the sequence of SEQ ID NO:
- 15,
- the CDRL3 has the sequence of SEQ ID NO:
- 16,
- the CDRH1 has the sequence of SEQ ID NO:
- 21,
- the CDRH2 has the sequence of SEQ ID NO:
- 22, and
- the CDRH3 has the sequence of SEQ ID NO:
- 23, according to North;
- (ii) the CDRL1 has the sequence of SEQ ID NO:
- 253,
- the CDRL2 has the sequence YTS,
- the CDRL3 has the sequence of SEQ ID NO:
- 16,
- the CDRH1 has the sequence of SEQ ID NO:
- 254,
- the CDRH2 has the sequence of SEQ ID NO:
- 255, and
- the CDRH3 has the sequence of SEQ ID NO:
- 23, according to IMGT;
- (iii) the CDRL1 has the sequence of SEQ ID NO:
- 20,
- the CDRL2 has the sequence of SEQ ID NO:
- 187,
- the CDRL3 has the sequence of SEQ ID NO:
- 16,
- the CDRH1 has the sequence of SEQ ID NO:
- 291,
- the CDRH2 has the sequence of SEQ ID NO:
- 292, and
- the CDRH3 has the sequence of SEQ ID NO:
- 293, according to Kabat;
- or
- (iv) the CDRL1 has the sequence of SEQ ID NO:
- 20,
- the CDRL2 has the sequence of SEQ ID NO:
- 187,
- the CDRL3 has the sequence of SEQ ID NO:
- 16,
- the CDRH1 has the sequence of SEQ ID NO:
- 325,
- the CDRH2 has the sequence of SEQ ID NO:
- 326, and
- the CDRH3 has the sequence of SEQ ID NO:
- 293, according to Chothia;
- and wherein the CD33-binding antibody or antigen binding fragment thereof is part of an anti-CD33 immunotoxin, an anti-CD33 antibody-drug conjugate, an antibody-fluorophore conjugate, an anti-CD33 antibody-radioisotope conjugate, or an anti-CD33 multispecific antibody.
46 more elements
A kit comprising a composition comprising
- a first binding domain comprising a first six-member complementarity determining region (CDR) set having a first CDRL1, a first CDRL2, a first CDRL3, a first CDRH1, a first CDRH2, and a first CDRH3, wherein
- the first CDRL1 has the sequence of SEQ ID NO:
- 20, the first CDRL2 has the sequence of SEQ ID NO:
- 15, the first CDRL3 has the sequence SEQ ID NO:
- 16, the first CDRH1 has the sequence of SEQ ID NO:
- 21, the first CDRH2 has the sequence of SEQ ID NO:
- 22, and the first CDRH3 has the sequence of SEQ ID NO:
- 23, according to North;
- and
- a second binding domain comprising a second six-member CDR set having a second CDRL1, a second CDRL2, a second CDRL3, a second CDRH1, a second CDRH2, and a second CDRH3 wherein:
- the second CDRL1 has the sequence of SEQ ID NO:
- 180, the second CDRL2 has the sequence of SEQ ID NO:
- 229, the second CDRL3 has the sequence SEQ ID NO:
- 182, the second CDRH1 has the sequence of SEQ ID NO:
- 230, the second CDRH2 has the sequence of SEQ ID NO:
- 231, and the second CDRH3 has the sequence of SEQ ID NO:
- 232, according to North;
- the second CDRL1 has the sequence of SEQ ID NO:
- 198, the second CDRL2 has the sequence of SEQ ID NO:
- 229, the second CDRL3 has the sequence SEQ ID NO:
- 182, the second CDRH1 has the sequence of SEQ ID NO:
- 240, the second CDRH2 has the sequence of SEQ ID NO:
- 241, and the second CDRH3 has the sequence of SEQ ID NO:
- 242, according to North;
- the second CDRL1 has the sequence of SEQ ID NO:
- 202, the second CDRL2 has the sequence of SEQ ID NO:
- 243, the second CDRL3 has the sequence SEQ ID NO:
- 204, the second CDRH1 has the sequence of SEQ ID NO:
- 244, the second CDRH2 has the sequence of SEQ ID NO:
- 245, and the second CDRH3 has the sequence of SEQ ID NO:
- 246, according to North;
- the second CDRL1 has the sequence of SEQ ID NO:
- 186, the second CDRL2 has the sequence of SEQ ID NO:
- 15, the second CDRL3 has the sequence SEQ ID NO:
- 188, the second CDRH1 has the sequence of SEQ ID NO:
- 233, the second CDRH2 has the sequence of SEQ ID NO:
- 234, and the second CDRH3 has the sequence of SEQ ID NO:
- 235, according to North;
- or
- the second CDRL1 has the sequence of SEQ ID NO:
- 192, the second CDRL2 has the sequence of SEQ ID NO:
- 236, the second CDRL3 has the sequence SEQ ID NO:
- 194, the second CDRH1 has the sequence of SEQ ID NO:
- 237, the second CDRH2 has the sequence of SEQ ID NO:
- 238, and the second CDRH3 has the sequence of SEQ ID NO:
- 239, according to North.
43 more elements
Dependencies are inferred from the claim text.